BCOR is a gene that encodes for an epigenetic regulator involved in the specification of cell
differentiation and body structure development and takes part in the noncanonical polycomb …

Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal
tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic …

Many sarcomas contain gene fusions that can be pathogenetic mechanisms and diagnostic
markers. In this article we review selected fusion sarcomas and techniques for their …

The fifth edition of the World Health Organization classification of soft tissue and bone
tumors redefined Ewing sarcoma by fusions between EWSR1/FUS and ETS family of …

Aims BCOR gene alteration is a genetic signature of rare subsets of sarcomas. Most BCOR‐
associated sarcomas thus far reported are in the pediatric population, except for uterine …

High-grade endometrial stromal sarcoma (HGESS) may harbor YWHAE-NUTM2A/B fusion,
ZC3H7B-BCOR fusion, and BCOR internal tandem duplication (ITD). NTRK3 upregulation …

The introduction of molecular methods into the diagnostics of central nervous system (CNS)
tumours and the subsequent deciphering of their molecular heterogeneity has resulted in a …

Renal tumors comprise approximately 7% of all malignant pediatric tumors. This is a highly
heterogeneous group of tumors, each with its own therapeutic management, outcome, and …

Abstract Purpose of Review Pediatric renal tumors account for 7% of new cancer diagnoses
in children. Here, we will review results from recently completed clinical trials informing the …

BCOR is an epigenetic regulator and is genetically altered by mutation, deletion, or gene
fusion in a range of cancers.“Central nervous system high-grade neuroepithelial tumor with …